Therapeutic methods
AssigneeArizona Board of Regents on behalf of Arizona State University
InventorsPamela Marshall, Peter Jurutka, Carl Wagner
Life of this patent
Estimating the term…
Abstract
The invention provides a method for a disease or condition associated with dopamine deficiency (e.g. depression, schizophrenia, or Parkinson's disease) in a mammal in need of such treatment comprising administering a compound that binds to RXR to the mammal.
Claims16
A method for treating a disease or condition associated with dopamine deficiency in a mammal in need of such treatment comprising administering a compound that binds to RXR to the mammal, provided the compound that binds to RXR is not bexarotene, wherein the compound that binds to RXR is a compound of formula XXX:
- wherein:
- the bond represented by --- is a single bond or a double bond;
- ring B is optionally substituted with one or more (i.e., 1, 2, or 3) groups independently selected from halo, hydroxy, carboxy, cyano, nitro, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, —B(OH)2, and —SO3H, wherein each (C1-C6)alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, and (C1-C6)alkanoyloxy, is optionally substituted with one or more groups independently selected from halo, hydroxy, nitro, cyano, (C1-C6)alkoxy, and oxo (═O);
- D is
- and
- ring A is a phenyl ring or a 6-membered heteroaryl ring other than pyridyl, which phenyl ring or 6-membered heteroaryl ring other than pyridyl is optionally substituted with one or more groups independently selected from halo, hydroxy, carboxy, cyano, nitro, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoyloxy, —B(OH)2, and —SO3H, wherein each (C1-C6)alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, and (C1-C6)alkanoyloxy, is optionally substituted with one or more groups independently selected from halo, hydroxy, carboxy, nitro, cyano, oxo (═O), —B(OH)2, and —SO3H;
- or a pharmaceutically acceptable salt thereof, wherein the disease or condition associated with dopamine deficiency is Parkinson's disease.
A method for treating a disease or condition associated with dopamine deficiency in a mammal in need of such treatment comprising administering a compound that binds to RXR to the mammal, wherein the compound that binds to RXR is a compound selected from:
- or a pharmaceutically acceptable salt thereof, wherein the disease or condition associated with dopamine deficiency is Parkinson's disease.
A method for treating a disease or condition associated with dopamine deficiency in a mammal in need of such treatment comprising administering a compound that binds to RXR to the mammal, provided the compound that binds to RXR is not bexarotene, wherein the compound that binds to RXR is a compound of formula IV:
- wherein:
- ring A is a phenyl ring or a 6-membered heteroaryl ring other than pyridyl, which phenyl ring or 6-membered heteroaryl ring other than pyridyl is optionally substituted with one or more groups independently selected from halo, hydroxy, cyano, nitro, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, and (C1-C6)alkanoyloxy, wherein each (C1-C6)alkyl, (C3-C6)cycloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, and (C1-C6)alkanoyloxy, is optionally substituted with one or more groups independently selected from halo, hydroxy, nitro, cyano, and oxo (═O);
- R2 is —COOH, —B(OH)2, or —SO3H;
- and
- D is
- or a pharmaceutically acceptable salt thereof, wherein the disease or condition associated with dopamine deficiency is Parkinson's disease.
A method for treating a disease or condition associated with dopamine deficiency in a mammal in need of such treatment comprising administering a compound that binds to RXR to the mammal, wherein the compound that binds to RXR is compound
- or a pharmaceutically acceptable salt thereof, wherein the disease or condition associated with dopamine deficiency is Parkinson's disease.
Dependencies are inferred from the claim text.